Department of Nutrition and Dietetics, Internal Medicine, VU University Medical Center, Amsterdam; Department of Nutrition and Health, Faculty of Health and Social Studies, HAN University of Applied Sciences, Nijmegen, The Netherlands.
Department of Clinical Medicine, Sapienza University, Rome, Italy.
Ann Oncol. 2018 May 1;29(5):1141-1153. doi: 10.1093/annonc/mdy114.
Driven by reduced nutritional intakes and metabolic alterations, malnutrition in cancer patients adversely affects quality of life, treatment tolerance and survival. We examined evidence for oral nutritional interventions during chemo(radio)therapy.
We carried out a systematic review of randomized controlled trials (RCT) with either dietary counseling (DC), high-energy oral nutritional supplements (ONS) aiming at improving intakes or ONS enriched with protein and n-3 polyunsaturated fatty acids (PUFA) additionally aiming for modulation of cancer-related metabolic alterations. Meta-analyses were carried out on body weight (BW) response to nutritional interventions, with subgroup analyses for DC and/or high-energy ONS or high-protein n-3 PUFA-enriched ONS.
Eleven studies were identified. Meta-analysis showed overall benefit of interventions on BW during chemo(radio)therapy (+1.31 kg, 95% CI 0.24-2.38, P = 0.02, heterogeneity Q = 21.1, P = 0.007). Subgroup analysis showed no effect of DC and/or high-energy ONS (+0.80 kg, 95% CI -1.14 to 2.74, P = 0.32; Q = 10.5, P = 0.03), possibly due to limited compliance and intakes falling short of intake goals. A significant effect was observed for high-protein n-3 PUFA-enriched intervention compared with isocaloric controls (+1.89 kg, 95% CI 0.51-3.27, P = 0.02; Q = 3.1 P = 0.37). High-protein, n-3 PUFA-enriched ONS studies showed attenuation of lean body mass loss (N = 2 studies) and improvement of some quality of life domains (N = 3 studies). Overall, studies were limited in number, heterogeneous, and inadequately powered to show effects on treatment toxicity or survival.
This systematic review suggests an overall positive effect of nutritional interventions during chemo(radio)therapy on BW. Subgroup analyses showed effects were driven by high-protein n-3 PUFA-enriched ONS, suggesting the benefit of targeting metabolic alterations. DC and/or high-energy ONS were less effective, likely due to cumulative caloric deficits despite interventions. We highlight the need and provide recommendations for well-designed RCT to determine the effect of nutritional interventions on clinical outcomes, with specific focus on reaching nutritional goals and providing the right nutrients, as part of an integral supportive care approach.
由于营养摄入减少和代谢改变,癌症患者的营养不良会对生活质量、治疗耐受性和生存产生不利影响。我们研究了化疗(放疗)期间口服营养干预的证据。
我们对随机对照试验(RCT)进行了系统评价,这些试验采用饮食咨询(DC)、旨在提高摄入量的高能口服营养补充剂(ONS)或富含蛋白质和 n-3 多不饱和脂肪酸(PUFA)的 ONS 补充剂,另外还旨在调节与癌症相关的代谢改变。对营养干预对体重(BW)的反应进行了荟萃分析,并对 DC 和/或高能 ONS 或高蛋白 n-3 PUFA 强化 ONS 进行了亚组分析。
确定了 11 项研究。荟萃分析显示,营养干预在化疗(放疗)期间对 BW 有总体获益(+1.31kg,95%CI 0.24-2.38,P=0.02,异质性 Q=21.1,P=0.007)。亚组分析显示,DC 和/或高能 ONS 没有效果(+0.80kg,95%CI -1.14 至 2.74,P=0.32;Q=10.5,P=0.03),这可能是由于依从性有限,摄入量低于目标摄入量。与等热量对照相比,高蛋白 n-3 PUFA 强化干预具有显著效果(+1.89kg,95%CI 0.51-3.27,P=0.02;Q=3.1,P=0.37)。高蛋白、n-3 PUFA 强化 ONS 研究显示,瘦体重丢失减少(N=2 项研究)和某些生活质量领域改善(N=3 项研究)。总体而言,这些研究数量有限,存在异质性,并且没有足够的能力显示对治疗毒性或生存的影响。
本系统评价提示化疗(放疗)期间营养干预对 BW 有总体积极影响。亚组分析显示,这些效果是由高蛋白 n-3 PUFA 强化 ONS 驱动的,表明靶向代谢改变的益处。DC 和/或高能 ONS 的效果较差,可能是由于干预后累积热量不足。我们强调需要并提供建议,进行精心设计的 RCT,以确定营养干预对临床结果的影响,特别关注达到营养目标和提供正确的营养,作为综合支持性护理方法的一部分。